3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
15
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
5
Head and Neck Neoplasms
4
Lung Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Neuroblastoma
2
Adenocarcinoma
2
Wilms Tumor
1
Stomatitis
1
Squamous Cell Cancer of Head and Neck (SCCHN)
1
Skin Neoplasms
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Radiation Injuries
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Pelvic Neoplasms
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Radiotherapy, Image-Guided
×
Clear all
NCT05328505
2026-03-24
MIDAS-Prostate
University Health Network, Toronto
Phase NA
Recruiting
80 enrolled